Merck & Co. (MRK) announced a multi‑year collaboration with Tempus AI, a technology company that specializes in AI‑driven precision medicine, on March 3, 2026. The partnership is designed to accelerate the discovery and development of biomarkers that can guide the use of Merck’s oncology therapies and potentially extend into other therapeutic areas.
The agreement will combine Tempus’s Lens platform—an AI and advanced analytics system built on one of the world’s largest libraries of multimodal data—with Merck’s clinical development expertise. While the financial terms of the deal were not disclosed, the collaboration builds on a prior relationship that has already produced joint research initiatives. The expanded partnership signals Merck’s intent to deepen its precision‑medicine capabilities beyond its existing PD‑L1 focus.
Merck’s Q4 2025 results, released on February 3, 2026, showed GAAP earnings per share of $1.19 and non‑GAAP EPS of $2.04 on worldwide sales of $16.4 billion, beating consensus estimates. However, the company’s FY 2026 non‑GAAP EPS guidance of $5.00–$5.15 and revenue guidance of $65.5–$67.0 billion fell short of analyst expectations, reflecting a one‑time charge related to the Cidara acquisition and a cautious outlook for the coming year.
George Addona, Senior Vice President of Discovery, Preclinical Development and Translational Medicine, said, "This collaboration with Tempus positions Merck to advance our precision oncology strategy through the application of the latest AI/ML capabilities to discover novel precision biomarkers, identify mechanisms of cancer cell resistance, and inform rational combinations for drugs in our early pipeline." Ryan Fukushima, CEO of Data & Apps at Tempus, added, "This collaboration builds on our existing relationship and reflects our shared commitment to harnessing the power of multimodal datasets with AI to deliver better options for patients."
Investors remained cautious following the guidance miss, with market focus on how the partnership may offset future revenue challenges such as the Keytruda patent cliff. The collaboration is viewed as a strategic move to enhance Merck’s R&D productivity and strengthen its competitive position in the rapidly evolving precision‑medicine landscape.
revised_sentiment_rating
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.